PDF(Pubmed)
Abstract：
Individuals with hereditary pancreatic cancer risk include high risk individuals (HRIs) with germline genetic susceptibility to pancreatic cancer (PC) and/or a strong family history of PC. Previously, studies have shown that PC surveillance in HRIs can downstage PC diagnosis and extend survival leading to pancreatic surveillance being recommended for certain HRIs. However, the optimal surveillance strategy remains uncertain, including which modalities should be used for surveillance, how frequently should surveillance be performed, and which sub-groups of HRIs should undergo surveillance. Additionally, in the ideal world PC surveillance should also be cost-effective. Cost-effectiveness analysis is a valuable tool that can consider the costs, potential health benefits, and risks among various PC surveillance strategies. In this review, we summarize the cost-effectiveness of various PC surveillance strategies for HRIs for hereditary pancreatic cancer and provide potential avenues for future work in this field. Additionally, we include cost-effectiveness studies among individuals with new-onset diabetes (NoD), a high-risk group for sporadic PC, as a comparison.
摘要：
具有遗传性胰腺癌风险的个体包括对胰腺癌(PC)具有种系遗传易感性和/或PC的强家族史的高风险个体(HRIs)。以前,研究表明,HRIs中的PC监测可以降低PC诊断并延长生存期,从而推荐对某些HRIs进行胰腺监测.然而,最佳监视策略仍然不确定，包括哪些模式应该用于监测，监控应该多久进行一次，以及哪些HRIs亚组应该接受监测。此外,在理想的世界中，PC监控也应该具有成本效益。成本效益分析是一种可以考虑成本的有价值的工具，潜在的健康益处，以及各种PC监控策略中的风险。在这次审查中,我们总结了针对遗传性胰腺癌HRI的各种PC监测策略的成本效益,并为该领域的未来工作提供了潜在的途径.此外,我们包括新发糖尿病（NoD）患者的成本效益研究，零星PC的高危人群，作为比较。
